Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
Status:
Enrolling by invitation
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
In this study, individuals without hepatitis C infection who are on the kidney transplant
waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be
treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg /
pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant
procedure and continued for 2 weeks post-renal transplant.